TGFβs, BMPs and Activins regulate numerous developmental and homeostatic processes and signal through hetero-tetrameric receptor complexes composed of two types of serine/threonine kinase receptors. Each of the 33 different ligands possesses unique affinities towards specific receptor types. However, the lack of specific tools hampered simultaneous testing of ligand binding towards all BMP/TGFβ receptors. Here we present a N-terminally Halo- and SNAP-tagged TGFβ/BMP receptor library to visualize receptor complexes in dual color. In combination with fluorescently labeled ligands, we established a Ligand Surface Binding Assay (LSBA) for optical quantification of receptor-dependent ligand binding in a cellular context. We highlight that LSBA is generally applicable to test (i) binding of different ligands such as Activin A, TGFβ1 and BMP9, (ii) for mutant screens and (iii) evolutionary comparisons. This experimental set-up opens opportunities for visualizing ligand-receptor binding dynamics, essential to determine signaling specificity and is easily adaptable for other receptor signaling pathways.
The transforming growth factor β (TGFβ) superfamily compromises more than 30 ligands, including bone morphogenetic proteins (BMPs) and activins, which regulate a broad range of developmental and homeostatic functions in a variety of cell types and organs, including the osteochondral and the vascular system1,2. TGFβ and BMP signal transduction is initiated by oligomerization of two type I and two type II serine/threonine kinase receptors upon binding one dimeric ligand. Trans-phosphorylation of the GS-box of a type I receptor by a type II receptor renders the type I receptor active, thereby allowing the recruitment and activation of SMAD proteins which act as transcriptional regulators2.
TGFβ superfamily ligands exhibit preferential binding to either type I or type II receptors. BMPs were described to possess high affinity towards type I receptors, which induce SMAD1/5/8 signaling, e.g. BMP9 for ALK1, BMP6 for ALK2 and BMP2 for ALK33,4,5. In contrast SMAD2/3 activating TGFβ superfamily members exhibit high affinity towards type II receptors, e.g. TGFβ1 for TGFBR2 or Activin A for ACVR2B5,6,7. However, some receptors are promiscuous in ligand binding (e.g. ACVR2B) and receptor expression levels vary in specific cell types. When high-affinity receptors are absent this often results in cell type-specific ligand competition scenarios between low-affinity receptors8.
All TGFβ superfamily members are dimers that resemble two left hands with palms together, forming a butterfly-like structure. The dimeric ligand offers two ‘wrist’, ‘knuckle’, or ‘fingertip’ epitopes, which allows the binding of two type I and two type II receptors9,10. Indeed, structural variation in these ligands yields different binding modes of type I and type II receptors for the BMP, TGFβ, and Activin classes8,11. While both receptor types bind independently BMPs and Activins, TGFβ receptors bind cooperatively to TGFβs. Hereby TGFBR2 binds uniquely to the fingertips of TGFβ1–3, thus creating a shared epitope with the ligands for the low-affinity type I receptor ALK5 (i.e. cooperative binding)10. In contrast, ACVR2A, ACVR2B, and BMPR2 bind via hydrophobic interactions to the knuckle epitope12,13,14,15. High-affinity binding of BMP type I receptors to the wrist epitope can be attributed to a structurally unique α1 helix, which projects phenylalanine into a hydrophobic pocket of the ligands (e.g. ALK3) or forms polar bonds with both ligand monomers (ALK1), in a so-called lock-and-key mechanism12,16,17. Finally, Activins possess significant variability in the dimeric structure and are thought to become restrained upon type II receptor binding, adopting a conformation that together with the fingertips selects for type I receptor recruitment (i.e. conformational selection)6,11,13,18.
Whereas co-crystallization of the ligands with their respective receptor extracellular domains (ECD) but also extensive surface plasmon resonance (SPR) experiments provided the structural framework and in vitro ligand–receptor affinities, a spatiotemporal resolution of the complexes with full-length membrane-bound receptors could so far only be achieved via microscopic approaches. Using immunofluorescence co-patching of epitope-tagged BMP receptors allowed the identification of preformed receptor complexes (PFCs) and BMP-induced signaling complexes (BISCs)19. The dynamic association of BMP receptors into homo- and heterodimers and the resulting lateral diffusion was shown by fluorescence recovery after photobleaching (FRAP) and Patch/FRAP experiments19,20. The dynamics of the short-lived BMP-induced heteromeric receptor complex formation were investigated by using two-color single particle tracking (SPT) utilizing quantum dots (QDs)21. However, most of the previous approaches relied on antibody recognition of epitope-tagged receptors, resulting in unknown fluorophore stoichiometries, requiring long incubation times and restricting the analysis to fixed cells. To overcome this, tagging receptors with self-labeling enzymes would allow for live-time analysis using straightforward staining protocols. Self-labeling protein tags like the SNAP- (derived from mammalian O6-alkylguanine DNA alkyl transferase) or the Halo-tag (derived from bacterial haloalkane dehalogenase) specifically react with benzyl guanine (BG) or chloroalkane (CA), respectively, transferring one fluorophore of choice by means of covalent linkage, enabling fast and stoichiometric antibody-free labeling of a protein of interest (POI)22,23. Simultaneous application of both self-labeling protein tags for analysis of two POIs previously demonstrated a two-color visualization approach for intracellular targets24. The addition of sulfonate groups to SNAP- and Halo-tag ligands renders them cell-impermeable and thereby allows discrimination of receptor populations by exclusively staining cell surface exposed receptors25,26.
In order to visualize all TGFβ/BMP receptors including their complexes in dual color we generated a comprehensive N-terminally Halo- and SNAP-tagged receptor library. Additionally, designing and applying fluorescently labeled growth factor ligands allowed us to not only monitor receptor-dependent ligand surface binding but also to establish a Ligand Surface Binding Assay (LSBA) for screening ligand binding under native conditions. As LSBA was suitable to test TGFβ superfamily ligand–receptor binding in living cells, this allowed us to provide additional proof for ligand–receptor interface specificities. To extend this, we designed and generated variants of type I and type II receptors with altered ligand specificities, as verified by microscopy. Further, we showed the general applicability of our system by for example comparing human receptor orthologs and distant teleost paralogs, providing a pre-testing platform before establishing animal models, thereby following the 3R principles. This work provides a new adaptable visualization platform for color multiplexing, suitable for super-resolution microscopy, and allowing to investigate ligand specificities to their respective receptor in living cells.
Cell surface staining of Halo- and SNAP-tagged BMP-, Activin- and TGFβ-receptors
BMPs, TGFβs, and Activins signal through binding towards different combinations of BMP/TGFβ type I and type II receptors in a hetero-tetrameric receptor–ligand complex (Fig. 1a). For example, the type I and the type II receptor ECD bind to the wrist and knuckle epitope of BMP family ligands, respectively (Fig. 1b). We here aimed to visualize preferential ligand–receptor binding on living cells using state of the art imaging tools. Limited visualization of BMP and TGFβ receptors by immunofluorescence can be overcome by utilization of self-labeling Halo- and/or SNAP-tag enzymes. BMP/TGFβ receptors, including type I receptors (hALK1-ALK6, rALK7, and hALK2-R206H) and type II receptors (hACVR2A, hACVR2B, hBMPR2, and hTGFBR2) were, therefore, N-terminally fused with Halo- or SNAP-tags separated by a 5x glycine linker downstream the signal peptide sequence, to obtain the receptor library shown in Fig. 1c. All Halo- and SNAP-tagged type I and type II receptor constructs were transiently expressed in COS-7 cells and lysates were subjected to Western blot analysis with specific antibodies directed against Halo- (Supplementary Fig. 1a) or SNAP-tags (Supplementary Fig. 1b). While untagged type I receptors have molecular weights between ~56 and 60 kDa, the Halo- or SNAP-tagged type I receptors were detected at a molecular weight corresponding to the addition of a Halo-tag (~33 kDa) or a SNAP-tag (~20 kDa) (Supplementary Fig. 1a, b). Similar weight shifts were observed for Halo- and SNAP-tagged type II receptors BMPR2, ACVR2A, ACVR2B, and TGFBR2 (Supplementary Fig 1a, b). Further, all Halo- and SNAP-tagged receptors were positively detected using impermeable CA-Alexa488 or BG-Alexa488 staining, respectively. Using cell-impermeable dyes provides the advantage to visualize exclusively the surface receptor pool, while cell-permeable dyes or fluorescent protein tags (e.g. GFPs) would stain both the membrane and intracellular fraction. As an example, we stained COS-7 cells transiently expressing ALK1-SNAP with first cell-impermeable SNAP-tag substrate BG-ATTO594, chased by cell-permeable BG-SiR, highlighting the advantage of surface-only staining (Fig. 1d). ATTO594 uniquely stained receptors located at the plasma membrane while SiR visualizes the crowded intracellular fraction. With the additional advantage that stimulated emission depletion (STED) compatible dyes were used, super-resolution imaging allowed a lateral resolution of ~40 nm pixel (Supplementary Fig. 1c). Together, this describes a comprehensive library of BMP and TGFβ receptors and showcases that CA- and BG-coupled dyes that allow the exclusive study of the cell surface population by STED nanoscopy.
High-affinity binding of Activin A by BMP type II receptors
Specificity of Activin A binding to BMP/TGFβ receptors was previously mainly studied in cell-free SPR measurements utilizing immobilized receptor ECDs and soluble Activin A13,18. Binding and chemical crosslinking of 125I-labeled Activin A in transfected COS-7 cells27,28 allowed for the detection of ligand-bound receptors after cell lysis by radiography. Here, we aimed to visualize receptor-dependent Activin A binding on living transfected COS-7 cells in a fluorescence-based approach. Fluorescently labeled Activin A was recently used to show ACVR2B clustering29. Accordingly, we have labeled dimeric Activin A with Cy5 and established an analysis pipeline for assessment of Activin A-Cy5 binding on COS-7 cells dependent on the expression of various Halo-tagged receptors (Fig. 2a). Receptors from the Halo-tagged BMP/TGFβ receptor library (Fig. 1c) were transiently expressed in COS-7 cells and stained with cell-impermeable Halo-tag substrate CA-Alexa488 at 4 °C to impede internalization. Simultaneous incubation with Activin A-Cy5 allowed for visualization of ligand binding to the respective receptor. Acquired confocal images were semi-automatically analyzed with Fiji ImageJ to quantify Activin A-Cy5 and receptor signal intensities (Fig. 2a). As expected ACVR2B led to the highest (~84-fold) Activin A binding, followed by ACVR2A (~29-fold) and BMPR2 (~27-fold), whereas TGFBR2 and all type I receptors showed no significant increase in Activin A binding (Fig. 2b, c, Supplementary Fig. 2a, b). Activin A-Cy5 and receptor intensities positively correlated for ACVR2A, ACVR2B, and BMPR2, while TGFBR2 expression did not correlate with ligand binding, highlighting that increased high-affinity receptor expression allows more ligand binding (Fig. 2d). Similar results were obtained using U2OS cells, highlighting that LSBA can be performed in multiple cell types with different endogenous receptor expression levels (Supplementary Fig. 3). Live cell imaging (LCI) of COS-7 cells expressing ACVR2B-Halo highlighted that Activin A-Cy5 binding occurs already within minutes after ligand addition (Supplementary Movie 1 and Supplementary Fig. 4). Finally, we tested if FACS analysis could be employed for measurement of ligand binding. Indeed, high-affinity binding of Activin A to ACVR2B or ACVR2A- expressing cells- (~13.7-fold or ~8.9-fold, respectively) was observed, whereas BMPR2-expressing cells (~2.8-fold) showed less binding and TGFBR2-expressing cells no binding. This highlights the general applicability of LSBA across different detection platforms, from which microscopic analysis provides higher sensitivity (Supplementary Fig. 5). Overall, these results are in accordance with binding and cross-linking studies in COS cells utilizing 125I-Activin A27, as well as SPR studies using immobilized receptors5 but reflect binding on living cells and under native conditions.
SiR-d12 labeled-BMP9 and -TGFβ1 allow for the identification of their respective high-affinity receptors
To extend the studies to other members of the TGFβ ligand superfamily, we labeled dimeric BMP9 and TGFβ1 with N-hydroxysuccinimide (NHS) silicon rhodamine-d12 (SiR-d1230) esters (Supplementary Fig. 6) to obtain far-red fluorescent BMP9-SiR-d12 and TGFβ-SiR-d12 (Fig. 3a; center). The labeling protocol is described in the “Methods” section and a scheme of SiR-d12-labeled ligands binding to their respective high-affinity Halo-tagged receptors and staining parameters are depicted in Fig. 3a (left and right). We next tested TGFβ1-SiR-d12 and BMP9-SiR-d12 binding on COS-7 cells, transiently expressing receptors found in signaling complexes of the respective ligand, i.e. TGFβ1-TGFBR2-ALK5 and BMP9-ACVR2B-ALK112,31. As expected, we observed strong TGFβ1-SiR-d12 binding to cells expressing TGFBR2 but not to cells expressing ALK5 (Fig. 3b). Similarly, the BMP9-high affinity receptor ALK1 strongly increased binding of BMP9-SiR-d12, while ACVR2B, which was shown by SPR to exhibit a similar high picomolar affinity (ALK1-Fc KD = 31.3 pM, ACVR2B-Fc KD = 33.0 pM)12, failed in binding BMP9-SiR-d12 (Fig. 3b, c). Both TGFβ1-SiR-d12 and BMP9-SiR-d12 signal intensity positively correlated to TGFBR2 or ALK1 receptor intensity, respectively (Fig. 3d). Finally, we expanded our ligand surface binding assay to the whole receptor library but did not observe any other significant increases for either TGFβ1-SiR-d12 or BMP9-SiR-d12 binding by any other receptor (Fig. 3c, d, Supplementary Figs. 7, 8). Structure prediction of Halo-tagged receptors highlights no interference of growth factor:receptor interface for any of the tested ligands, due to long flexible Gly5 linkers (Supplementary Fig. 9a, b). Equally, we confirmed that Halo-tagged receptors remain signaling competent (Supplementary Fig. 9c–f).
Receptor-mimics reveal critical residues for Activin A–type II receptor interfaces
Binding of Activin A-Cy5 to cell surface expressed type II receptors confirmed a higher affinity of ACVR2B over ACVR2A and BMPR2, which showed comparable ligand binding (Fig. 2)5. Structural analysis of Activin A bound to ACVR2B previously highlighted that the core of the concave ACVR2B interface contains hydrophobic residues, which interact with hydrophobic residues in the Activin A knuckle epitope, surrounded by polar residues at the edge that form strong electrostatic interactions (Fig. 4a)13. Sequence comparison of ACVR2B with ACVR2A indicated only subtle differences in two amino acids which form hydrophobic bonds with Activin A (TyrA2B60/PheA2A61, PheA2B82/IleA2A83), whereas BMPR2 is characterized by a different elongated 2/3 loop, which harbors mostly polar and charged amino acids of the Activin A epitope in ACVR2B (LeuA2B79-AspA2B80-AspA2B81-PheA2B82-AsnA2B83) (Fig. 4a). Evolutionarily conserved residues and potentially crucial for ligand binding properties in this area include Trp78 (Fig. 4a). We next asked if substituting half of the BMPR2 2/3 loop (Ser BR284-X-GlnBR290) with the Activin A-binding ACVR2B amino acids (LeuA2B79-X-AsnA2B83) would increase ligand binding of BMPR2. The resulting BMPR2Mimic-ACVR2B-Halo construct was generated (Supplementary Fig. 10a) and Activin A-Cy5 binding was analyzed as described above (Fig. 2a, Supplementary Fig. 10b). Indeed, BMPR2Mimic-ACVR2B showed increased binding compared to BMPR2 and even to ACVR2B, highlighting the crucial role of the 2/3 loop in Activin A ligand binding (Fig. 4b–d). We next asked whether the altered 2/3 loop in BMPR2Mimic-ACVR2B forms similar interactions with Activin A residues as ACVR2B. We, therefore, took advantage of the ACVR2B/Activin A crystal structure (PDB: 1S4Y)18 and the crystallized ECD of BMPR2 bound to Activin B (PDB: 7U5O)15,32 and performed in silico docking of the BMPR2 structure to Activin A (Supplementary Fig. 11). Next, we generated a homology model of BMPR2Mimic-ACVR2B docked on to Activin A. Indeed, our predictions highlight that BMPR2Mimic-ACVR2B forms the same electrostatic interactions as ACVR2B with Activin A at its 2/3 loop (most importantly a salt bridge between AspA2B80 with ArgActA87) (Fig. 4e), while in BMPR2 these interactions are altered (e.g. IleBR288 forms a less favorable interaction with ArgActA87). Collectively this data highlighted that our Halo-tagged receptor library is suitable for assessment of ECD mutation screening and that the substitution of the 2/3 loop of BMPR2 with the ACVR2B 2/3 loop yields an Activin A high-affinity BMPR2.
Generation of a BMP9-binding ALK2 receptor- ALK2Mimic-ALK1
After successfully increasing the affinity of a type II receptor (Fig. 4), we aimed to equally enhance the binding of BMP9-SiR-d12 to type I receptors. For this, we selected ALK2-Halo to substitute key residues from the high-affinity receptor ALK1. In line with our data (Fig. 3b, c), ALK1 is the high-affinity receptor for BMP93,12 and presents with a ~1800 times higher affinity (ALK1-Fc KD = 45.5 pM) when compared to ALK2 (ALK2-Fc KD = 83 nM)4. However, ALK2 was shown to transmit BMP9 signals in the absence of ALK1 in non-endothelial cells4,33,34,35. The ALK1–BMP9 interface is subdivided into three sites (I–III). Site I and III are overlapping with other type I receptor–BMP interfaces while site II is unique to ALK1 for BMP9 and BMP10 binding4,12. Alongside, the helix α1 and loop F3 of ALK1 contain charged residues (Fig. 5a), which through polar interactions convey binding to both BMP9 monomers within the wrist epitope4,12. These polar residues (HERR motif—His73, Glu75, Arg78, and Arg80) bridge to amino acids that are unique to BMP9 and BMP10, thereby defining ligand specificity4. Sequence comparison with ALK2 highlighted that the HERR motif surrounding the helix α1 is absent in ALK2, alongside other critical residues that define ALK1/BMP9 specificity (Fig. 5a). We, therefore, generated three ALK2 variants, in which we sequentially substituted amino acids by the ALK1/BMP9 epitope (V1–3 ALK2Mimic-ALK1) and tested BMP9-SiR-d12 surface binding in transfected COS-7 cells (Fig. 5b–d, Supplementary Fig. 12a, b). Interestingly, the substitution of the HERR motif only was not sufficient to increase BMP9-binding to ALK2 (V1 ALK2Mimic-ALK1), however additional substitution of hydrophobic residues surrounding the HERR motif in the helix α1 rendered ALK2 BMP9-sensitive (V2 ALK2Mimic-ALK1). Additional substitution of amino acids at the site I interface (VVFREE-motif, V3 ALK2Mimic-ALK1) did not further increase ligand binding. In line with increased BMP9 binding, V2 and V3 ALK2Mimic-ALK1 expression elevated BMP9-induced BRE-Luc activity similar to ALK1-Halo (Fig. 5e). To elucidate possible interactions of the ALK2 variants, we designed a homology model of each variant and docked it to BMP9 based on the ALK1/BMP9/ACVR2B complex (PDB:4FAO) and AlphaFold2 predictions of ALK2 (Supplementary Figs. 13, 14, Fig. 5f)12,36,37. Structure comparison underlined the incapability of the ALK2 helix α1 to form strong bonds at the wrist epitope (Fig. 5f). However, helix α1 of V2 but not of V1 ALK2Mimic-ALK1 can form interactions with BMP9, similarly as in ALK1 (Fig. 5f, Supplementary Fig. 14b). Substitution of the HERR motif in V1 ALK2Mimic-ALK1 is likely insufficient due to the rigidity and/or altered conformation of surrounding residues (e.g., ThrV179 versus GlyV2/ALK179), prohibiting the conformations of the mutated residues needed for interacting with BMP9 (Supplementary Fig. 14b). Although the binding interface of V3 ALK2Mimic-ALK1 and BMP9 was expected to resemble the ALK1 binding interface more closely, the F2 loop differs in its conformation when comparing ALK1 and V3 ALK2Mimic-ALK2, possibly due to the ALK2-derived overall fold and surrounding residues (Supplementary Fig. 14c). This likely explains the observed low binding of V3 ALK2Mimic-ALK1 to BMP9 (Fig. 5c). Together this indicates that exchanging critical residues of the helix α1 of ALK2 with ALK1 residues transfers BMP9 sensitivity.
Determining BMP9-binding to ALK1 teleost orthologs
Finally, labeled ligands are a useful tool to study receptor binding in in vivo systems. Nonetheless, ligand–receptor binding should and can be tested before going into animal experiments using LSBA. As an example, we tested BMP9 binding to different teleost (subcohort of Clupeocephala) ALK1 orthologs (Fig. 6). Both zebrafish (Danio rerio) and medaka (Oryzias latipes) are two well-characterized fish model systems and distant vertebrate relatives of humans (Fig. 6a). However, zebrafish and medaka ALK1 have a shortened F2 loop and unique pre-helix loops which differ from the human ALK1. Overall, in medaka 25% and in zebrafish only 20% of the human BMP9/ALK1 interface is conserved (Fig. 6b). Interestingly, binding of human BMP9 was also observed for both teleost ALK1s but at a reduced level compared to human ALK1 (Fig. 6c–e). Interestingly, transient expression of zebrafish or medaka ALK1 in HEK cells elevated BMP9-induced BRE-Luc activity to the same extent as via the human ALK1, suggesting the necessity of endogenous type II receptors for BMP9-signaling via the SMAD pathway (Fig. 6f, Supplementary Fig. 12c), which covers the different affinities to the single expressed respective type I receptors. In summary, LSBA is also applicable for pre-testing of animal models and evolutionary studies.
Interrogating cell surface receptor biology in living cells, including their distribution, stoichiometries, ligand-binding efficacies, and downstream activation has been pushed in the last years mainly by state-of-the-art microscopy techniques38,39. In all these instances, the choice of labeling the protein of interest is of immense importance40. While traditional fluorescent protein tagging is powerful, it comes with several drawbacks, such as delay in chromophore maturation, observation of intracellular signals, limited choice of different colors (especially in the far-red spectrum), and reduced performance in super-resolution nanoscopy due to bleaching. Small organic dyes overcome this issue, which are more robust and brighter and can be selectively targeted in a temporal manner to self-labeling enzymes, such as SNAP- and Halo-tags. Spatial resolution can furthermore be achieved by using membrane-impermeable substrates and dyes that restrict labeling to extracellularly exposed tags. Even more, the possibility to use orthogonal tags allows the use of different colors, rapidly adding to the portfolio of multiplexed experiments to visualize receptor pairs and their ligand interaction in live cells. Recent examples include the determination of SNAP-mGluR4 co-localization (with Cav2.1 and Bassoon) by two-color dSTORM microscopy39 and the compositional diversity of differently tagged-kainate receptor assembly by three-color single molecule TIRF microscopy41. Alternatively, visualization of cell surface ligand binding, endo- and exocytosis, as well as receptor clustering was achieved using ligands covalently linked to fluorophores29,42,43,44,45,46. For this, ligands were either directly labeled at deprotonated primary amines using NHS-activated fluorophores42,43, or through the introduction of an N- or C-terminal cysteine residue allowing for site-directed maleimide coupling of the dyes45,46.
Herein, we combined N-termin ally Halo- and SNAP-tagged BMP and TGFβ receptors with fluorescently labeled growth factors that allowed us to measure and to visualize ligand binding to cell surface receptors in living cells. Whereas ligand–receptor affinities are commonly assessed using in vitro methods such as surface plasmon resonance measurements, we attempted to measure ligand binding on living cells with the ability to resolve subcellular ligand binding events. Applying this Ligand Surface Binding Assay (LSBA) allowed for binding measurements under more physiological conditions with a focus on the plasma membrane. While in this study we focused on the binding properties of single receptors, future studies can include additional binding partners. Whereas crosslinking experiments using radio-labeled growth factors have been performed as one of the first methods to define high- and low-affinity BMP/TGFβ receptor affinities7,47,48, the use of fluorescently labeled ligands increases the field of application to multiple microscopy techniques. By using labeled Activin A it was recently shown that ligand-mediated receptor clustering depends on the presence of ACVR2A/B29. Earlier studies using labeled BMP2 gave insights into ligand uptake and release43,44,45.
To test whether N-terminally Halo-/SNAP-tagged receptors are still capable of ligand binding we performed the LSBA using different members of the TGFβ superfamily of ligands (Activin A, TGFβ1 and BMP9), which are known to possess high affinities towards different type I or type II receptors. Our findings from LSBA measurements using Activin A-Cy5 are in good agreement with previous binding and crosslinking studies using radiolabeled ligands, highlighting that only the BMP/Activin type II receptors are capable of Activin A binding and they do not require the presence of type I receptors27,28,49. SPR analysis confirmed that ACVR2BECD exhibited the highest affinity (KD = 1.1 nM) followed by ACVR2AECD (KD = 5.7 nM) and BMPR2ECD (KD = 59 nM)5. Receptor dimerization will further enhance Activin A binding as indicated by SPR studies using ACVR2A-Fc (KD ~ 130 pM) and BMPR2-Fc (KD ~ 14 nM)49, which was further confirmed by a comparison of Activin A binding to a single ECD ACVR2B-Fc (KD = 108 pM) versus a homodimeric (ACVR2B)2-Fc (KD = 12.5 pM)6. Interestingly, BMPR2–Activin A complexes have been suspected to be more transient due to their higher dissociation rate, compared to ACVR2A-Activin A49. These differences are confirmed by sequence comparison of the ACVR2B–Activin A interface with ACVR2A and BMPR2 ECD sequences. While ACVR2A shares mostly the same 2/3 loop with ACVR2B, which contains polar and charged amino acids that are critical for Activin A binding, BMPR2 has an alternative 2/3 loop13. We could show that substitution of these critical residues elevated Activin A binding to BMPR2 by ~3 fold. In the same light, substitution (H87A) of a sterically unfavorable Histidine located in the 2/3 loop led to a 1.5-fold increase of 125I-Activin A surface binding in CHO cells49. Together this highlights that the LSBA is suitable for mutant screening and assessment of high-affinity ligand binders.
We next performed fluorescent labeling of BMP9 and TGFβ1, using a recently reported, state-of-the-art silicon rhodamine-d12 (SiR-d12) as its NHS ester, which exhibits high brightness and increased lifetime, and as such is suitable for confocal, life-time and super-resolution microscopy30. Both BMP9-SiR-d12 and TGFβ1-SiR-d12 bound their known high-affinity receptor, i.e. ALK1 and TGFBR2, respectively3,7. Interestingly, whereas BMP9 is supposed to signal via ALK2 in non-endothelial cells that lack ALK1 expression4,33,34,35, we did not observe BMP9 binding by any other type I receptor except ALK1. This is in line with the described difference of ALK1 being ~1800 times more sensitive to BMP9 than ALK2 as determined by SPR4. BMP9 is secreted into the bloodstream from stellate cells in the liver50. In the vasculature BMP9 circulates at concentrations (2–12 ng/mL) that are ~100 times higher than the EC50 of BMP9 to ALK1 (EC50 = 50 pg/mL, 2 pM)3,51, highlighting that endothelial cells, which express predominantly ALK1 as type I receptor, are exposed to saturating BMP9 conditions. BMP9 signaling via ALK2 was reported to play a role in a variety of non-endothelial cells52. Mechanistically, this was supported by radioactive crosslinking studies which observed BMP9–ALK2 binding in myoblasts and breast cancer cells53. Further, the authors highlighted that co-expression of BMP type II receptors in COS-7 cells enhances BMP9 binding to ALK2. While local BMP9 expression has been described in the developing murine CNS54, the predominant source of BMP9 in the human body is circulating BMP9 originating from the liver51. Therefore, ALK2-dependent BMP9 signaling in non-endothelial cells could play a prominent role in the context of leaky or injured vessels accompanied by blood spillage into the tissue. In line with multiple reports of BMP9 influencing tumor progression52, tumors are characterized by immature leaky blood vessels55. Similarly, BMP9 could fulfill its previously described pro-osteogenic function56 in the context of bone fracture healing.
Most of the ALK1–BMP9 interface is unique12, which is why we sequentially substituted key residues of ALK2 with corresponding residues of ALK1. Particularly substituting the amino acids of the pre-helix loop and the helix α1 was sufficient to increase BMP9 binding to V2 ALK2Mimic-ALK1. Interestingly, we did not detect ACVR2B dependent BMP9 binding, while SPR studies using ACVR2B-Fc and ALK1-Fc indicated a similar affinity of BMP9 for both receptors12. A potential explanation could be that a stable dimer of ACVR2B, as present in the Fc-fusion protein, is required for the high-affinity binding of BMP9, which might not be the case for the full-length receptors at the plasma membrane. While a comparative study for ACVR2B binding to BMP9 has to our knowledge not been performed, monomeric ALK1-ECD (KD ~ 71.6 pM) possesses a lower affinity to BMP9 compared to dimerized ALK1-Fc (KD ~ 48.1 pM)4. It is unlikely that BMP9 binding to ACVR2B was negatively influenced by the N-terminal Halo-tag, as the same receptor was able to bind Activin A normally4,12,13. However, an independent SPR study highlighted that the affinity of Activin A (KD ~ 9.2 pM) towards ACVR2B-Fc is eleven times higher than the affinity of BMP9 (KD ~ 116.1 pM)57. Furthermore, administration of ACVR2B-Fc as a GDF8/Myostatin inhibitor (ACE-031) in a clinical trial to treat Duchenne muscular dystrophy had to be stopped due to the occurrence of telangiectasias58, typical of deficient BMP9-signaling in the vasculature. Together, this highlights that BMP9 efficiently binds to monomeric ALK1 at low concentrations, as well as to hetero- (e.g. ALK2/ACVR2B) or homodimeric receptor complexes (ACVR2B/ACVR2B).
Whereas we have shown that the LSBA assay is a valuable method to study surface ligand sequestration of high-affinity ligand:receptor pairs, a current limitation of the assay is the capability to measure ligand binding mediated by heterodimeric receptor complexes. Future studies, therefore, have to address how to quantify the effect of type I and type II co-expression, which would require equal expression levels of both. Also, it will be interesting to expand the receptor library towards known and novel BMP- and TGFβ-co-receptors and subsequently test, if ligand binding to the receptors is dependent on the presence of respective co-receptors. Since all tested high-affinity ligand:receptor pairs recapitulated previously reported binding behaviors, a negative influence of N-terminal receptor-tagging on ligand-binding could be excluded. While N-terminal Halo-tags in combination with non-permeable dyes allow the exclusive study of receptors at the cell surface, C-terminal tagging in combination with permeable Halo-dyes would allow the visualization of also internal receptor pools. Further, the future development of smaller self-labeling enzymatic tags would be a great advancement in the field. Comparing ligand binding by both microscopic and FACS analysis highlighted that both methods have individual advantages. While the microscopic LSBA is capable to detect endogenous ligand binding and subtle differences in ligand-binding at subcellular resolution and in a time-dependent manner, FACS analysis allows the unbiased quantification of a high number of cells. A disadvantage of FACS-based analysis is the requirement of an enzymatic step for cell detachment, which could deteriorate receptor:ligand binding. The LSBA on the other hand can be performed on fixed and living cells without cell detachment. Since our current studies were limited to three ligands, each representative for one TGFβ ligand sub-family, it will be intriguing to expand the analysis to other members of the TGFβ superfamily, and potentially include heterodimeric ligands such as BMP9/BMP10. Therefore site-directed labeling strategies in combination with dual-color labeling might be required to efficiently assess hetero-dimeric ligand binding.
In summary, we established an imaging platform that allows us to revise and test ligand–receptor affinities in a cellular context. Due to the nature of the self-labeling Halo- and SNAP-tag, BMP and TGFβ receptors can now be visualized at a stoichiometric ratio using modern dyes, which meet the requirements for the respective experiments, e.g impermeability for surface-only stainings, increased photo-stability including STEDability26,30. Future studies can now address (1) differences in ligand–receptor binding of monomeric receptors vs. receptor complexes, (2) binding behavior of other TGFβ-superfamily ligands using the incorporation of unnatural amino acids at the C-terminus allowing site-directed coupling and positioning of fluorophores, and (3) visualization of endogenous receptor populations in living cells and in tissues using fluorescently labeled high-affinity ligands as a replacement for insufficient antibodies.
First, hBMPR2-LF-SNAP/Halo and mUnc5b-SNAP/Halo were generated by substitution of meGFP in hBMPR2-LF-meGFP and mUnc5b-meGFP (doctoral thesis J. Jatzlau) with SNAP or Halo using Sec-61-Halo and pSNAPf as a template24. For the generation of the N-terminally Halo- and SNAP-tagged BMP/TGFβ receptor library, hALK1-hALK6, rALK7,hALK2-R206H as well as mAlk1 and zAlk1 were subcloned into pcDNA3.1 mUnc5b-SNAP/Halo and hACVR2A, hACVR2B, hTGFBR2 were subcloned into pcDNA3.1 hBMPR2-LF-SNAP/Halo in between EcoRI and NotI thereby replacing the respective receptor ORF. Receptor encoding sequences with respective restriction site overhangs have been amplified using the primers listed in Supplementary Table 1. All cloning PCRs were carried out on a Peltier Thermal Cycler PTC-200 and the primers used are listed in (Appendix Table 1). The elongation time was adapted according to the product size (Phusion Pol. = 1 kb/min). PCR products were resolved by agarose gel electrophoresis and purified using NucleoSpin Gel and PCR Clean-up kit, according to the manufacturer’s guidelines. For restriction cloning, PCR products and 3 µg of the destination vector were digested overnight with 1 µL (~20 Units) of each restriction enzyme. Successful restriction digest was validated on an agarose gel, from where cleaved products were purified. Subsequently, 50 ng destination vector and 300 ng insert were ligated for 10 min at room temperature with T4 ligase (~40 Units) in 10 µL H2O. After 5 min heat inactivation at 65 °C, the total volume of ligation mix was added to 50 µL chemically competent DH5α or TOP10 E. coli and incubated for 30 min on ice. After a 90 s heat shock in a 42 °C water bath, the bacteria were put back on the ice for 2 min. Next, the bacteria were shaken for 1 h at 37 °C and 180 rpm in 1 mL LB medium w/o antibiotics. Finally, bacteria were plated on LB-agar plates with antibiotics and grown overnight at 37 °C. On the next day, 3 mL LB medium with the respective antibiotics was inoculated with bacterial colonies and grown at 37 °C and 180 rpm overnight, followed by plasmid DNA purification and Sanger sequencing.
COS-7 and U2-OS cells were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FCS, 2 mM l-glutamine, and penicillin (100 units/mL)/streptomycin (100 µg/mL) (DMEM full medium) in a humidified atmosphere at 37 °C and 5% CO2 (v/v). COS-7 and U2-OS cells were maintained in T175 flasks and cells were split 1:3 or 1:5, depending on need, and were kept sub-confluent. For passaging, cells were washed once with PBS before being removed from the flasks surface with trypsin/EDTA (0.05/0.02% in PBS).
Transient transfection with expression plasmids
For microscopy studies of COS-7 and U2-OS cells, cells were transfected with Lipofectamine 2000 according to the manufacturer’s instructions. 100,000 cells/12-well were seeded in 1 mL DMEM full medium. On the following day, cells in each well were transfected with a total amount of 500 ng DNA. The subsequent experimental procedure took place 24 h post-transfection unless indicated otherwise.
SDS–PAGE and Western-blotting
For sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), treated cells were lysed in 150 µL Laemmli buffer and frozen at −20 °C. The lysate was pulled through an 18-gauge syringe and boiled for 10 min at 95 °C. 10% polyacrylamide gels were cast in advance and stored at 4 °C until usage. Separated by their molecular weight, proteins were transferred onto methanol-activated PVDF membranes by Western-blot. Membranes were blocked for 1 h in 0.1% TBS-T containing 3% w/v BSA, washed three times in 0.1% TBS-T and incubated with indicated primary antibodies overnight at 4 °C. Primary antibodies: anti-GAPDH (Cell Signaling; #2118; monoclonal rabbit antibody), anti-Halo (ProMega; #G9211; monoclonal mouse antibody), and anti-SNAP (Invitrogen; #CAB4255; polyclonal rabbit antibody) were applied at a 1:1000 dilution in 3% w/v bovine serum albumin (BSA)/fraction V in TBST. For HRP-based detection, goat-α-mouse or goat-α-rabbit IgG HRP conjugates (±0.8 mg/mL, Dianova; #111-035-144, #115-035-068) were used at a dilution of 1:10,000. Chemiluminescent reactions were processed using WesternBright Quantum HRP substrate (advansta) and documented on a FUSION FX7 digital imaging system.
Halo- and SNAP-tagged receptor staining and ligand visualization
For visualization of COS-7 and U2-OS cells transiently expressing Halo- and SNAP-receptor fusion proteins, 200,000 cells were transfected on glass coverslips (confocal: 18 mm ø or STED: precision #1.5H 10 mm ø) with desired constructs. For live cell imaging, 100,000 COS-7 cells were seeded on glass-bottom culture dishes (35 mm ø). 24 h post-transfection, cells were washed once with PBS and incubated, depending on the experimental setup, with a fluorescent SNAP- and/or a fluorescent Halo-ligand in the absence or presence of fluorescent growth factors for 30 min. The following commercially available cell-impermeable fluorescent ligands were utilized: HaloTag Fluorescent Ligand Alexa Fluor 488 (Promega, #G1002) in the following abbreviated as CA-Alexa488; SNAP-Surface 594 (NEB, #S9134S) in the following abbreviated as BG-ATTO594 and SNAP-Cell 647-SiR (NEB, # S9102S), in the following abbreviated as BG-SiR. Surface receptor staining was carried out at 4 °C, whereas incubation at 37 °C took place when studying growth factor binding on living cells. Cells were washed once with PBS, before fixation with 100% methanol for 5 min. Cells were washed with PBS once more and mounted with Fluoromount G (confocal microscopy).
Preparation of fluorescently labeled recombinant Activin A
Mature dimeric Activin A was prepared by refolding from inclusion bodies as described before for Atto-647 and CF640R-labeled activin A29 with the exception that mature activin A was untagged and the label used here was NHS-activated Cy5 (Lumiprobe, cat. no 13020). NHS-Cy5 was dissolved in DMSO to a concentration of 3 mM and lyophilized activin A dissolved in 10 mM HCl to 763 µM (10 mg/mL). The protein:dye ratio in labeling was 1:2 and final concentrations were 76 μM Activin A and 153 μM NHS-Cy5 in 50 mM HEPES pH 7.4, 30% acetonitrile in the total volume of 125 µL. The labeling reaction was incubated for 3 h at 23 °C and excess unreacted dye was quenched by adding Tris and ethanolamine to a final concentration of 8 mM each. The labeling sample was acidified by diluting the sample to 2 mL with 0.1% trifluoroacetic acid and loaded into ACE5 C8 300 4.6 × 250 mm reversed-phase chromatography column equilibrated with 10% acetonitrile, 0.1% trifluoroacetic acid. The protein was eluted with a linear gradient to 90% acetonitrile, 0.1% trifluoroacetic acid in 40 mL with a flow rate of 1 mL/min. Protein was detected at 280 and 646 nm (Cy5 excitation maximum). Fractions with Cy5 absorbance were analyzed for labeling efficiency spectrophotometrically using Cy5 molar extinction coefficient at 646 nm of 250,000 L mol−1 cm−1, activin A protomer extinction coefficient at 280 nm of 18,050 L mol−1 cm−1 and abs280nm/abs646nm correction factor for Cy5 of 0.04 (LumiProbe product data sheet) to account for dye absorbance at 280 nm. Fractions with at most 1:1 ratio of dye:activin protomer were pooled, divided into 5 µg aliquots, dried in black tubes using a centrifugal vacuum concentrator, and stored at −80 °C.
Cell stimulation with growth factors
rhBMP9/GDF2 and rhTGFβ1 (PeproTech, Hamburg, Germany) were reconstituted and stored according to the manufacturer’s instructions. For microscopical binding studies, COS-7 cells were stimulated with 2 nM Activin A-Cy5. For microscopical binding studies (COS-7) of SiR-d12- or labeled growth factors, cells were stimulated with 0.3 nM TGFβ1-SiR-d12 and 0.3 nM BMP9-SiR-d12 if not indicated otherwise.
Fluorescent growth factor labeling and Ligand Surface Binding Assay (LSBA)
For fluorescent labeling of dimeric BMP9 and TGFβ1, N-hydroxysuccinimidyl deuterated silicon rhodamine (NHS-SiR-d12) (Supplementary Note 1) was taken up in DMSO to a final concentration of 1 mM. Lyophilized rhBMP9 (Peprotech) and rhTGFβ1 (Peprotech) were reconstituted in 0.2 M sodium bicarbonate (reaction buffer), pH = 8.3, to obtain a final concentration of 2 µM. NHS-SiR-d12 was then added to the reconstituted ligands at a 5-fold molar excess. Final concentrations being at 2 µM (Protein) and 10 µM (NHS-Dye). The mixture was allowed to incubate at room temperature for 4 h. Meanwhile, a 0.5 mL Amicon Ultra 10 kDa molecular weight cutoff column (Merck Millipore, UFC501024) was calibrated with reaction buffer and centrifuged at 14,000×g at 4 °C without drying the filter. The reaction mixture was then gently applied onto the pre-calibrated column and centrifuged for 4 min, while never allowing the filter to dry. Subsequently, the filter was gently washed with reaction buffer ad 500 µL and centrifuged as described before. This washing procedure was repeated twice. Afterward, 50 µL sterile Millipore H2O was added to the column, before the column was inverted and put in a fresh elution tube and centrifuged as described above. The column was rinsed with 30 µL sterile Millipore H2O and eluted as in the previous step. Protein concentration was determined with a NanoDrop 2000 spectrophotometer (Thermo Fischer). For visualization of SiR-d12-ligand binding on COS-7 cells, cells were transfected as described above with corresponding high- and low-affinity Halo receptors. The day after, cells were washed with PBS and, additionally to fluorescent Halo-ligand CA-Alexa488, simultaneously incubated with fluorescent growth factors at previously indicated concentrations for 30 min at 4 °C. Subsequently, cells were washed once with ice-cold PBS before fixation with 100% methanol for 5 min. Cells were washed again with PBS and mounted with Fluoromount G (confocal microscopy) or ProLong Gold Antifade Mounting reagent (STED microscopy).
Fluorescence-activated cell sorting (FACS)
For FACS analysis of ligand binding towards COS-7 cells transiently expressing Halo-receptor fusion proteins, 600,000 cells were transfected in six wells with desired constructs. 24 h post-transfection, cells were placed on ice and washed twice with ice-cold DPBS followed by incubation with fluorescent Halo-ligand CA-Alexa488 (0.5 µM) in the absence or presence of Activin A-Cy5 (2 nM) for 30 min at 4 °C. Subsequently, cells were washed once with ice-cold DPBS before incubation with Accutase solution at RT for 15 min. After detachment, cells were resuspended in DPBS and centrifuged at (1000 n/min) for 5 min. Finally, cells were resuspended in PBS (100 mM EDTA) and measured in BD LSRFortessa™ Cell Analyzer. FACS data were analyzed using the BD FACSDiva 8.0.1 software. Cells were gated first for single cells using SSC-A/FSC-A, followed by the gating of 1000 transfected cells with a high signal in the FITC channel. Activin A-Cy5 surface binding was quantified as the mean Cy5 intensity of AF488+ cells.
Confocal and STED microscopy
Confocal and stimulated emission depletion (STED) data of fixed or living COS-7 cells were acquired with the Expert Line STED Microscope from Abberior. Confocal images of COS-7 cells expressing Halo-tagged receptors stained with CA-Alexa488 and fluorescent ligands (Cy5- and SiR-d12-labeled) were acquired using 485 nm (20% laser power) and 640 nm excitation (20% laser power). STED images were acquired using 561 nm excitation for ATTO 594 (20% laser power) and 640 nm excitation for SiR (2% laser power). A 775 nm STED laser at 10% laser power was used to deplete both dyes. Live cell confocal imaging of COS-7 cells transiently expressing ACVR2B-Halo was carried out at an Abberior Expert Line STED microscope at a physiological temperature of 37 °C using a stage-top incubator (okolab). Cells were stained with 0.5 µM Halo-tag substrate CA-AlexaFluor488 (Promega) for 30 min at 37 °C, washed extensively, and kept on ice in HEPES buffer pH 7.4 until imaging. Focussing on transfected and stained cells, Activin A-Cy5 was added to the cells at 2 nM and dual-color images were acquired for 2 min every 2 s. Confocal and STED Images were acquired with the following settings in the Abberior Imspector Acquisition & Analysis Software v16.3: objective lens: ×100 NA1.4 (oil) [UPLS], pinhole: 1.0 AU, range: 75 µm × 75 µm, confocal pixel size: 60 nm, STED pixel size: 20 nm, pixel dwell time: 5/10 µs.
Image analysis and semi-automated quantification with Fiji ImageJ
Confocal raw data were post-processed and adjusted for color and contrast (linear adjustments maintained for confocal datasets represented within one figure) using Fiji (ImageJ) software and Adobe Photoshop (Adobe Systems). Surface binding quantification of Activin A-Cy5, BMP9-SiR-d12, and TGFβ1-SiR-d12 on COS-7 cells transiently expressing SNAP- & Halo-Receptor constructs was performed with Fiji. Per cell, four regions of interest (ROI) (100 µm²) were chosen and the raw integrated intensity (RawIntDen) of each ROI was measured both in receptor and ligand channels. Per condition, 10–30 cells were quantified in three independent experiments. Receptor–ligand binding was calculated relative to intensity values of untransfected COS-7 cells, representing endogenous ligand–receptor binding. Linear regression and correlation analysis of RawIntDen values of receptors and ligands was performed and plotted in GraphPad Prism 8.0 (GraphPad Software Inc.). Maximum RawIntDen values of receptors were normalized to 1. All used scripts are available under https://github.com/Habacef/Supplementary-scripts-for-LSBA (https://doi.org/10.5281/zenodo.7389579)59.
Dual-Luciferase Reporter gene Assay
HEK293T cells were transfected with indicated Halo-tagged and HA-tagged Type I and/ or Type II receptors together with the SMAD1/5/8 sensitive (BRE)2 or SMAD2/3 sensitive (CAGA)12 luciferase reporter. A constitutively expressing construct encoding renilla luciferase (RL-TK; Promega) was co-transfected as an internal control. The next day, cells were starved in serum-free medium for 5 h before stimulation with BMP9 (0.2 nm) for 24 h. Cell lysis was performed using passive lysis buffer (Promega) and measurement of luciferase activity was carried out according to the manufacturer’s instructions using a TECAN initiate f200 Luminometer (TECAN).
Statistics and reproducibility
All statistical tests were performed using GraphPad Prism version 9.3 software and are listed in the figure legends. The normal distribution of data sets was tested with the Shapiro–Wilk normality test. In cases of failure to reject the null hypothesis, the ANOVA and Tukey’s post hoc test was used to check for statistical significance under the normality assumption. For all experiments, statistical significance was assigned, with an alpha level of p < 0.05. All Box-plots are defined as: center line, median; box limits, 10–90 quartiles; whiskers, 1.5× interquartile range; points, outliers. Each experiment was performed at least three independent times on different days (n = 3).
The receptor variant BMPR2Mimic-ACVR2B was modeled starting from a BMPR2 x-ray structure (PDB: 7U5O15. The receptor variants V1 ALK2Mimic-ALK1, V2 ALK2Mimic-ALK1 and V3 ALK2Mimic-ALK1 were modeled starting from the AlphaFold2 prediction of ALK236,37, as the topology of the ECD of ALK2 is not yet experimentally solved. The starting structures were prepared by adding missing loops and residues using the GreedyOptMutationMover60,61 (if applicable) followed by coordinate-constrained relaxation protocol to obtain optimized H-bonds based on the Rosetta Energy Function 2015(ref2015)_cst score function within RosettaScripts62. The GreedyOptMutationMover was also used to generate 500 replicas of each of the variants via insertion of mutations (and if applicable a short, up to 3 AA long, loop modeling). Within the same RosettaScript, a full FastRelax63,64 with the filters “BuriedUnsatHBonds” and “PackStat” was performed for each generated variant. The best variants were discriminated by plotting the RMSD of all heavy backbone atoms vs. the Rosetta-Score (using scoring function ref2015) of the final 500 variants. The RMSD was calculated against the input structures (either BMPR2 or ALK2) using the RMSDMetric mover65 in RosettaScripts. The 10 variants with low REU-values (score) and low RMSD were visually inspected, and the most reliable structure based on convincing intramolecular interactions and comparison to known BMP-receptor-ECDs was used for receptor–ligand-docking. The described plots together with cartoon representations of all variants are shown in Figs. S11a, S13a. All used RosettaScripts can be found in an open-source repository under https://github.com/Habacef/Supplementary-scripts-for-LSBA (https://doi.org/10.5281/zenodo.7389579)59.
Receptor ligand docking
All homology models of receptor variants, but also the X-ray structure of BMPR2 and the AlphaFold prediction of ALK2 were docked to Activin A and BMP9, respectively. BMPR2 and BMPR2Mimic-ACVR2B were superimposed to Activin A-bound ACVR2B (X-ray structure PDB: 1S4Y). ALK2, V1 ALK2Mimic-ALK1, V2 ALK2Mimic-ALK1 and V3 ALK2Mimic-ALK1 were superimposed to BMP9-bound ALK1 (X-ray-structure PDB: 4FAO12). As the receptor binding interfaces (Fig. S11a) are known, local Monte-Carlo-based protein-protein docking could be performed in 500 replicas. Here, first, the “Docking” mover was used with low-resolution (backbone plus centroid) flags before a high-resolution (full atom) docking (using ref2015 scoring function). Other parameters as distance perturbation and angle perturbation were left on default. The Interface RMSD (IRMSD) was plotted against the score of the interface residues (ISC). Here too, the best 10 hits showing the lowest IRMSD and lowest ISC were screened for the final docked homology model. The described plots together with cartoon representations of all variants are shown in Figs. S11b, S13b. All used scripts are available under https://github.com/Habacef/Supplementary-scripts-for-LSBA (https://doi.org/10.5281/zenodo.7389579)59.
Graphical schemes and figures
Figures were created with BioRender.com and PyMOL, Available at http://www.pymol.org/pymol.
(Schrödinger, L. & DeLano, W., 2020.)
For additional information regarding materials and methods, see the Appendix Supplementary Methods.
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
All used scripts described in this study are available under https://github.com/Habacef/Supplementary-scripts-for-LSBA (https://doi.org/10.5281/zenodo.7389579)59.
Hiepen, C., Yadin, D., Rikeit, P., Dorpholz, G. & Knaus, P. Actions from head to toe: an update on bone/body morphogenetic proteins in health and disease. Cytokine Growth Factor Rev. 27, 1–11 (2016).
Nickel, J. & Mueller, T. D. Specification of BMP signaling. Cells 8, https://doi.org/10.3390/cells8121579 (2019).
David, L., Mallet, C., Mazerbourg, S., Feige, J. J. & Bailly, S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109, 1953–1961 (2007).
Salmon, R. M. et al. Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms. Nat. Commun. 11, 1621 (2020).
Heinecke, K. et al. Receptor oligomerization and beyond: a case study in bone morphogenetic proteins. BMC Biol. 7, 59 (2009).
Goebel, E. J. et al. Structures of activin ligand traps using natural sets of type I and type II TGFbeta receptors. iScience 25, 103590 (2022).
Cheifetz, S. et al. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48, 409–415 (1987).
Martinez-Hackert, E., Sundan, A. & Holien, T. Receptor binding competition: a paradigm for regulating TGF-beta family action. Cytokine Growth Factor Rev. 57, 39–54 (2021).
Yadin, D., Knaus, P. & Mueller, T. D. Structural insights into BMP receptors: specificity, activation and inhibition. Cytokine Growth Factor Rev. 27, 13–34 (2016).
Groppe, J. et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell 29, 157–168 (2008).
Goebel, E. J. et al. Structural characterization of an activin class ternary receptor complex reveals a third paradigm for receptor specificity. Proc. Natl Acad. Sci. USA 116, 15505–15513 (2019).
Townson, S. A. et al. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J. Biol. Chem. 287, 27313–27325 (2012).
Thompson, T. B., Woodruff, T. K. & Jardetzky, T. S. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions. EMBO J. 22, 1555–1566 (2003).
Kirsch, T., Nickel, J. & Sebald, W. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J. 19, 3314–3324 (2000).
Chu, K. Y., Malik, A., Thamilselvan, V. & Martinez-Hackert, E. Type II BMP and activin receptors BMPR2 and ACVR2A share a conserved mode of growth factor recognition. J. Biol. Chem. 298, 102076 (2022).
Kirsch, T., Sebald, W. & Dreyer, M. K. Crystal structure of the BMP-2–BRIA ectodomain complex. Nat. Struct. Biol. 7, 492–496 (2000).
Goebel, E. J., Hart, K. N., McCoy, J. C. & Thompson, T. B. Structural biology of the TGFbeta family. Exp. Biol. Med. 244, 1530–1546 (2019).
Greenwald, J. et al. A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Mol. Cell 15, 485–489 (2004).
Nohe, A. et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem. 277, 5330–5338 (2002).
Marom, B., Heining, E., Knaus, P. & Henis, Y. I. Formation of stable homomeric and transient heteromeric bone morphogenetic protein (BMP) receptor complexes regulates Smad protein signaling. J. Biol. Chem. 286, 19287–19296 (2011).
Guzman, A. et al. SMAD versus non-SMAD signaling is determined by lateral mobility of bone morphogenetic protein (BMP) receptors. J. Biol. Chem. 287, 39492–39504 (2012).
Juillerat, A. et al. Directed evolution of O6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo. Chem. Biol. 10, 313–317 (2003).
Los, G. V. et al. HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem. Biol. 3, 373–382 (2008).
Bottanelli, F. et al. Two-colour live-cell nanoscale imaging of intracellular targets. Nat. Commun. 7, ARTN 10778 https://doi.org/10.1038/ncomms10778(2016)
Poc, P. et al. Interrogating surface versus intracellular transmembrane receptor populations using cell-impermeable SNAP-tag substrates. Chem. Sci. 11, 7871–7883 (2020).
Birke, R. et al. Sulfonated red and far-red rhodamines to visualize SNAP and Halo-tagged cell surface proteins. Org. Biomol. Chem. https://doi.org/10.1039/d1ob02216d. (2022).
Attisano, L., Wrana, J. L., Cheifetz, S. & Massague, J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 68, 97–108 (1992).
Donaldson, C. J., Mathews, L. S. & Vale, W. W. Molecular cloning and binding properties of the human type II activin receptor. Biochem. Biophys. Res. Commun. 184, 310–316 (1992).
Ramachandran, A. et al. Pathogenic ACVR1(R206H) activation by Activin A-induced receptor clustering and autophosphorylation. EMBO J. 40, e106317 (2021).
Rossmann, K. et al. N-Methyl deuterated rhodamines for protein labelling in sensitive fluorescence microscopy. Chem. Sci. 13, 8605–8617 (2022).
Radaev, S. et al. Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J. Biol. Chem. 285, 14806–14814 (2010).
Mace, P. D., Cutfield, J. F. & Cutfield, S. M. High resolution structures of the bone morphogenetic protein type II receptor in two crystal forms: implications for ligand binding. Biochem. Biophys. Res. Commun. 351, 831–838 (2006).
Luo, J. et al. TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J. Biol. Chem. 285, 29588–29598 (2010).
Kang, Q. et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther. 11, 1312–1320 (2004).
Olsen, O. E. et al. Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer J. 4, e196 (2014).
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
Varadi, M. et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439–D444 (2022).
Borgarelli, C. et al. Lighting up the plasma membrane: development and applications of fluorescent ligands for transmembrane proteins. Chemistry 27, 8605–8641 (2021).
Siddig, S. et al. Super-resolution imaging reveals the nanoscale organization of metabotropic glutamate receptors at presynaptic active zones. Sci. Adv. 6, eaay7193 (2020).
Sahl, S. J., Hell, S. W. & Jakobs, S. Fluorescence nanoscopy in cell biology. Nat. Rev. Mol. Cell Biol. 18, 685–701 (2017).
Selvakumar, P. et al. Structural and compositional diversity in the kainate receptor family. Cell Rep. 37, 109891 (2021).
Nanda, J. S. & Lorsch, J. R. Labeling a protein with fluorophores using NHS ester derivitization. Methods Enzymol. 536, 87–94 (2014).
Alborzinia, H. et al. Quantitative kinetics analysis of BMP2 uptake into cells and its modulation by BMP antagonists. J. Cell Sci. 126, 117–127 (2013).
Trujillo, S. et al. Engineered 3D hydrogels with full-length fibronectin that sequester and present growth factors. Biomaterials 252, 120104 (2020).
Paarmann, P. et al. Dynamin-dependent endocytosis of Bone Morphogenetic Protein2 (BMP2) and its receptors is dispensable for the initiation of Smad signaling. Int. J. Biochem. Cell Biol. 76, 51–63 (2016).
Ast, J. et al. Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics (vol. 11, 467, 2020). Nat. Commun. 11, ARTN 5160 https://doi.org/10.1038/s41467-020-19101-4 (2020).
Mitchell, E. J. & O’Connor-McCourt, M. D. A transforming growth factor beta (TGF-beta) receptor from human placenta exhibits a greater affinity for TGF-beta 2 than for TGF-beta 1. Biochemistry 30, 4350–4356 (1991).
Nishitoh, H. et al. Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J. Biol. Chem. 271, 21345–21352 (1996).
Rejon, C. A. et al. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells. Cell Signal. 25, 2717–2726 (2013).
Miller, A. F., Harvey, S. A. K., Thies, R. S. & Olson, M. S. Bone morphogenetic protein-9—an autocrine/paracrine cytokine in the liver. J. Biol. Chem. 275, 17937–17945 (2000).
David, L. et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res. 102, 914–922 (2008).
Mostafa, S. et al. The wonders of BMP9: from mesenchymal stem cell differentiation, angiogenesis, neurogenesis, tumorigenesis, and metabolism to regenerative medicine. Genes Dis. 6, 201–223 (2019).
Scharpfenecker, M. et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 120, 964–972 (2007).
Lopez-Coviella, I., Berse, B., Krauss, R., Thies, R. S. & Blusztajn, J. K. Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science 289, 313–316 (2000).
Azzi, S., Hebda, J. K. & Gavard, J. Vascular permeability and drug delivery in cancers. Front. Oncol. 3, 211 (2013).
Lamplot, J. D. et al. BMP9 signaling in stem cell differentiation and osteogenesis. Am. J. Stem Cells 2, 1–21 (2013).
Li, J. et al. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J. Clin. Investig. 131, https://doi.org/10.1172/JCI138634 (2021).
Campbell, C. et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55, 458–464 (2017).
Obendorf, L. & Burdzinski, W. Supplementary-scripts-for-LSBA: LSBA-scripts-v1. Zenodo https://doi.org/10.5281/zenodo.7389579 (2022).
King, C. et al. Removing T-cell epitopes with computational protein design. Proc. Natl Acad. Sci. USA 111, 8577–8582 (2014).
Nivón, L. G., Bjelic, S., King, C. & Baker, D. Automating human intuition for protein design. Proteins: Struct. Funct. Bioinforma. 82, 858–866 (2014).
Fleishman, S. J. et al. RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite. PLoS ONE 6, e20161 (2011).
Khatib, F. et al. Algorithm discovery by protein folding game players. Proc. Natl Acad. Sci. USA 108, 18949–18953 (2011).
Maguire, J. B. et al. Perturbing the energy landscape for improved packing during computational protein design. Proteins 89, 436–449 (2021).
Adolf-Bryfogle, J. et al. Growing glycans in rosetta: accurate de novo glycan modeling, density fitting, and rational sequon design. Preprint at bioRxiv https://doi.org/10.1101/2021.09.27.462000 (2021).
We thank Ramona Birke for her technical assistance. J.J. was supported by the Deutsche Forschungsgemeinschaft DFG (BSRT, SFB958) and the Einstein Center ECRT. W.B. was supported by an Einstein Kickbox grant for young scientists from the Einstein Center for Regenerative Therapies. P.K. acknowledges the support from Deutsche Forschungsgemeinschaft DFG (FOR2165; SFB1444), the Einstein Center ECRT, Morbus Osler Society, and BMBF (PrevOP-Overload). We would like to acknowledge the assistance of the Core Facility BioSupraMol FU Berlin supported by the DFG. F.B. was supported by the Deutsche Forschungsgemeinschaft DFG (SFB958).
Open Access funding enabled and organized by Projekt DEAL.
The authors declare no competing interests.
Peer review information
Communications Biology thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editor: Manuel Breuer. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jatzlau, J., Burdzinski, W., Trumpp, M. et al. A versatile Halo- and SNAP-tagged BMP/TGFβ receptor library for quantification of cell surface ligand binding. Commun Biol 6, 34 (2023). https://doi.org/10.1038/s42003-022-04388-4